News for AIM ImmunoTech Inc Stock (AIM)

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

GlobeNewsWire • 03/15/24

AIM ImmunoTech Announces Launch of CEO Corner Platform

GlobeNewsWire • 03/07/24

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

GlobeNewsWire • 02/29/24

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

GlobeNewsWire • 02/14/24

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

GlobeNewsWire • 02/08/24

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

GlobeNewsWire • 01/24/24

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca's Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

GlobeNewsWire • 01/22/24

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

GlobeNewsWire • 01/10/24

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

Business Wire • 01/05/24

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied

PRNewsWire • 01/03/24

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board's Determination that Activist Group's Nominations Are Invalid

Business Wire • 12/29/23

AIM ImmunoTech Provides Update Regarding Annual Meeting

Business Wire • 11/28/23

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents

GlobeNewsWire • 11/28/23

AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

GlobeNewsWire • 11/21/23

AIM ImmunoTech Inc. (AIM) Q3 2023 Earnings Call Transcript

Seeking Alpha • 11/15/23

AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update

GlobeNewsWire • 11/15/23

Aimia, Inc. (AIMFF) Q3 2023 Earnings Call Transcript

Seeking Alpha • 11/14/23

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer

GlobeNewsWire • 11/14/23

AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast

GlobeNewsWire • 11/09/23

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

GlobeNewsWire • 11/08/23

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

GlobeNewsWire • 10/30/23

AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs

GlobeNewsWire • 10/17/23

AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

GlobeNewsWire • 09/22/23

AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Bre

GlobeNewsWire • 09/11/23

AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewsWire • 09/05/23